Braaten Marco, Weng Bob, Morrissey Reid, Asghar Muhammad Sohaib, Silberstein Peter, Jabbar Ali Bin Abdul, Abubakar Tauseef, Mirza Mohsin
Creighton University Department of Internal Medicine, CHI Health Bergan Mercy Hospital, Omaha, Nebraska, USA.
Mayo Clinic, Rochester, Minnesota, USA.
Ann Med Surg (Lond). 2025 Jun 13;87(8):4997-5002. doi: 10.1097/MS9.0000000000003485. eCollection 2025 Aug.
Evaluate survival outcomes of PN compared to RN in patients with T1-2, N0, M0 cRCC.
Patients with cRCC were identified using the National Cancer Database (NCDB). Inclusion criteria included T1-2, N0, M0 disease, treatment with either PN or RN, and a Charleston Deyo co-morbidity score of 0. Patients with missing survival data, advanced staging, or incomplete surgical information were excluded. Propensity score matching was performed to create identical groups with respect to age, sex, and race. Kaplan-Meier survival curves, multinomial logistic regression, and cox proportional hazard models were used for statistical analysis.
Of the 476 eligible propensity matched patients, 238 (50.0%) underwent PN and 238 (50.0%) underwent RN. PN was associated with better survival (mean: 186 vs. 170 months, < 0.05) and lower odds of death (OR = 3.43; 95% CI, 2.05-5.76; < 0.05). Five- and ten-year survival rates for PN were 95.2% and 91.1%, compared to 87.4% and 76.0% for RN. Patients treated with PN were significantly more likely to come from a higher income quartile and be treated at an academic/research facility.
Partial nephrectomy demonstrates superior survival and shorter hospital stays compared to radical nephrectomy in localized cRCC, reinforcing its role as the preferred surgical approach.
评估T1-2、N0、M0期局限性肾透明细胞癌患者接受肾部分切除术(PN)与根治性肾切除术(RN)后的生存结局。
利用国家癌症数据库(NCDB)识别肾透明细胞癌患者。纳入标准包括T1-2、N0、M0期疾病,接受PN或RN治疗,以及查尔斯顿-迪约合并症评分为0。排除生存数据缺失、分期较晚或手术信息不完整的患者。进行倾向评分匹配以创建年龄、性别和种族相同的组。采用Kaplan-Meier生存曲线、多项逻辑回归和Cox比例风险模型进行统计分析。
在476例符合倾向评分匹配的患者中,238例(50.0%)接受了PN,238例(50.0%)接受了RN。PN与更好的生存相关(平均:186个月对170个月,P<0.05)和更低的死亡几率(OR=3.43;95%CI,2.05-5.76;P<0.05)。PN的5年和10年生存率分别为95.2%和91.1%,而RN分别为87.4%和76.0%。接受PN治疗的患者更有可能来自较高收入四分位数,并且在学术/研究机构接受治疗。
与根治性肾切除术相比,局限性肾透明细胞癌患者接受肾部分切除术具有更好的生存率和更短的住院时间,强化了其作为首选手术方式的作用。